GlaxoSmithKline (GSK) Stock Rating Upgraded by Kepler Capital Markets

GSK has been the subject of a number of research reports.

Hedge funds and other institutional investors own 9.66% of the company's stock.

GlaxoSmithKline (NYSE:GSK) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a report issued on Wednesday, January 17th.

Are Suffering From Mental Stress? Then Adopt Pets to reduce stress
New Research which jointly Conducted by 3 United Kingdom universities has revealed that the pets can help to heal mental diseases. A new study shows pet ownership has significant benefits to people suffering from mental health problems.

GlaxoSmithKline plc (LON:GSK) had its price objective lowered by equities researchers at J P Morgan Chase & Co from GBX 1,750 ($23.59) to GBX 1,570 ($21.17) in a research report issued to clients and investors on Wednesday, September 13th, reports. BNP Paribas upgraded the stock to "Neutral" rating in Wednesday, April 5 report. UBS Group raised shares of GlaxoSmithKline from a "neutral" rating to a "buy" rating and upped their target price for the company from $35.04 to $35.85 in a report on Monday, November 27th. Finally, TheStreet raised shares of GlaxoSmithKline from a "c+" rating to a "b" rating in a report on Wednesday, October 25th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have issued a buy rating to the company. GlaxoSmithKline now has an average rating of "Hold" and a consensus price target of $38.57.

GlaxoSmithKline plc (GSK) traded up $0.32 on Friday, reaching $36.49. 5,872,260 shares of the company traded hands, compared to its average volume of 5,360,000. GlaxoSmithKline plc has a 1-year low of GBX 1,444.00 and a 1-year high of GBX 1,745.56. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.44 and a current ratio of 0.60.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.03. The business had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. sell-side analysts forecast that GlaxoSmithKline will post 2.8 earnings per share for the current fiscal year.

Briton Andrew Musgrave achieves country's best Winter Olympics result in cross-country skiing
Britain's Andrew Musgrave finished a battling seventh as Norway claimed all three medals in the men's 30km skiathlon at the Winter Olympics in Pyeongchang.

Several hedge funds have recently made changes to their positions in the company. FTB Advisors Inc. boosted its holdings in GlaxoSmithKline by 16.9% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 11,740 shares of the pharmaceutical company's stock worth $506,000 after purchasing an additional 115 shares in the last quarter. FinTrust Investment Advisory Services LLC bought a new position in GlaxoSmithKline in the 3rd quarter worth $401,000. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company's stock worth $520,827,000 after acquiring an additional 293,866 shares during the period. King Luther Capital Management Corp boosted its stake in GlaxoSmithKline by 1.0% in the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company's stock valued at $175,000 after buying an additional 788 shares during the last quarter. Private Advisor Group LLC raised its holdings in GlaxoSmithKline by 7.2% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company's stock worth $341,727,000 after acquiring an additional 569,600 shares during the period. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.94%. The ex-dividend date is Thursday, February 22nd. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.50. GlaxoSmithKline's dividend payout ratio is presently 237.21%.

ILLEGAL ACTIVITY WARNING: "GlaxoSmithKline (GSK) Rating Reiterated by Jefferies Group" was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another site, it was illegally copied and republished in violation of US & global copyright & trademark legislation. The stock of GlaxoSmithKline plc (NYSE:GSK) earned "Neutral" rating by BNP Paribas on Tuesday, September 15. The slowdown in sales of the Consumer Healthcare segment in 2017 is also a concern. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Modi, French PM discuss strengthening strategic partnership
India has started a Technology Park project here in Ramallah which is now under construction. Last summer, Modi visited Israel but did not stop over in the West Bank .

Últimas notícias